Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021 USD ($) subsidiary	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Summary of Significant Accounting Policies [Line Items]
Wholly-owned subsidiaries of Antares Pharma | subsidiary	2
Allowance for doubtful accounts balance	$ 0	$ 0
Write-offs to bad debt expense	0	0	$ 0
Revenue not yet recognized recorded in contract assets	$ 564,000	1,685,000
Finite-lived intangible assets, amortization method	straight-line basis
Goodwill	$ 1,095,000	1,095,000
Goodwill impairment loss	$ 0	0	$ 0
Cash discount to incentive for prompt payment	2.00%
Cash discounts offered by reducing accounts receivable	100.00%
Limited rights for product return, period before product expiration	6 months
Product Return Policy, Limited Rights, Period After Product Expiration	12 months
Remaining performance obligations	$ 14,879,000
Cash, cash equivalents and investments	65,913,000
Licensing and development revenue
Summary of Significant Accounting Policies [Line Items]
Revenue recognized	$ 3,889,000
Minimum
Summary of Significant Accounting Policies [Line Items]
Royalty payment period	45 days
Useful Life (in Years)	5 years
Product expiration period	24 months
Minimum | Insurance plans
Summary of Significant Accounting Policies [Line Items]
Rebate payment period	2 months
Minimum | Government
Summary of Significant Accounting Policies [Line Items]
Rebate payment period	3 months
Maximum
Summary of Significant Accounting Policies [Line Items]
Royalty payment period	60 days
Useful Life (in Years)	10 years
Product expiration period	33 months
Maximum | Insurance plans
Summary of Significant Accounting Policies [Line Items]
Rebate payment period	3 months
Maximum | Government
Summary of Significant Accounting Policies [Line Items]
Rebate payment period	6 months
Level 1 Input
Summary of Significant Accounting Policies [Line Items]
Cash and cash equivalents, remeasured and reported at fair value	$ 26,889,000	$ 36,133,000